Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2021)
Xeris Biopharma Holdings' (XERS) quarterly Gains from Investment Securities came in at $793000.0 in Q4 2021, up 1541.82% YoY from $48300.1 in Q4 2020, and up 1079.01% on a QoQ basis from -$81000.0 in Q3 2021.
Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 2 years of Gains from Investment Securities data on file, last reported at $793000.0 in Q4 2021.
- Quarterly Gains from Investment Securities rose 1541.82% year-over-year to $793000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $817000.0 (changed N/A YoY) and the FY2021 annual result came in at $702000.0, up 7700.0% from the prior year.
- Gains from Investment Securities improved to $793000.0 in Q4 2021, from -$81000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $793000.0 in Q4 2021 to a low of -$81000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 793,000.00 |
| Dec 31, 2021 | 793,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Dec 31, 2020 | -55,000.00 |
| Dec 31, 2020 | -55,000.00 |
| Sep 30, 2020 | 160,000.00 |
| Sep 30, 2020 | 160,000.00 |